Picture [iito] Männer Ballett 650x80px
Document › Details

BioNTech AG. (12/16/15). "Press Release: BioNTech to Attend and Present at 34th Annual JP Morgan Healthcare Conference 2016". Mainz.

Region Region San Francisco, CA
  Country United States (USA)
Organisations Organisation BioNTech AG
  Today BioNTech SE (Nasdaq: BNTX)
  Group BioNTech (Group)
  Organisation 2 JPMorgan Chase (Group)
Products Product J.P. Morgan 34th Annual Healthcare Conference 2016 San Francisco
  Product 2 RNA-based therapeutic
Index term Index term BioNTech–JPMorgan Chase: investor conference, 201601 supply service BioNTech presents at JP Morgan Healthcare Conference 2016
Persons Person Marett, Sean (BioNTech 202012 CBO + CCO 201506 COO before Evotec)
  Person 2 Sahin, Ugur (BioNTech 201207 Managing Director BioNTech + Ribological GmbH)

BioNTech AG, a fully integrated biotechnology company developing truly personalized cancer immunotherapies, today announced that Sean Marett, COO of BioNTech, will be presenting an overview of the company at the 34th Annual J.P. Morgan Healthcare Conference on Tuesday 12th January 2016 at 04:00 pm Pacific Standard Time. The event will be held at the Westin St. Francis Hotel in San Francisco.

Furthermore, the company’s management team, Prof. Dr. Ugur Sahin, CEO, Sean Marett, COO, and Dr. Sierk Poetting, CFO will all be attending the JP Morgan Healthcare conference.

The JP Morgan Healthcare Conference brings together corporate leaders, financial sponsors and institutional investors to explore market and sector trends. The 34th Annual Healthcare conference will be held on 11 – 14th January 2016 in San Francisco.


Notes to editors

About BioNTech AG

BioNTech AG is an immunotherapy leader with bench-to-market capabilities, developing truly personalized, well-tolerated & potent treatments for cancer and other diseases. Established by clinicians and scientists, the Group is pioneering disruptive technologies ranging from individualized mRNA based medicines through innovative Chimeric Antigen Receptors /T-cell Receptor-based products and novel antibody checkpoint immunomodulators. BioNTech’s clinical programs are supported by an in-house molecular diagnostics unit whose products include MammaTyper®, a molecular in-vitro diagnostic kit marketed under CE and IVD marking in Europe and certain other countries. Founded in 2008, BioNTech is privately held, with the Strüngmann Family Office as a majority shareholder. Information about BioNTech is available at


Regina Jehle
Tel: +49 (0) 6131 9084 1273

Hume Brophy
Mary Clark, Eva Haas, Hollie Vile
Tel: +44 20 3440 5657

Record changed: 2020-12-27


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for BioNTech (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Made Without Love 650x80px

» top